These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Infliximab--practical guidelines for the treatment of Crohn's disease].
    Author: Bauerfeind P, Beglinger C, Beltinger J, Braegger C, Eigenmann F, Fried M, Guyot J, Hürlimann R, Michetti P, Seibold F, Straumann A.
    Journal: Rev Med Suisse; 2006 Jul 26; 2(74):1807-15. PubMed ID: 16927560.
    Abstract:
    Infliximab is a monoclonal chimeric antibody, with high affinity and specificity for tumour necrosis factor alpha (TNFalpha) that plays a central role in the pathogenesis of immune mediated inflammatory disorders including Crohn's disease and ulcerative colitis. Globally over 600000 patients have been treated with infliximab to date. This global experience led to a better definition of the overall safety and efficacy profile of this medication. The goal of the present recommendations is to provide practical information to physicians involved in the care of patients with inflammatory bowel disease.
    [Abstract] [Full Text] [Related] [New Search]